In a landmark development for the field of regenerative medicine, Cellino Biotech, Inc. has been awarded up to $25 million in funding from the Advanced Research Projects Agency for Health (ARPA-H), a division within the U.S. Department of Health and Human Services. This grant will significantly advance Cellino’s NEBULA, a cutting-edge biomanufacturing technology designed to…
Radiant Biotherapeutics, a cutting-edge biotechnology firm specializing in advanced antibody therapies, has announced the successful closure of a $35 million Series A financing round. This significant investment, spearheaded by the Bill & Melinda Gates Foundation and Amplitude Ventures, aims to further develop Radiant’s innovative Multabody™ platform, which is poised to revolutionize therapeutic approaches across various…
In a significant boost for the Life Sciences industry, Qualifyze has announced a landmark $54 million Series B funding round. This investment, led by global software investment firm Insight Partners, alongside existing backers HV Capital, HarbourVest Partners, H14, and Cherry Ventures, is set to propel Qualifyze into a new phase of growth and innovation. With…
LifeSpan Vision Ventures has made a significant investment in Remedium Bio, a biotechnology firm renowned for its groundbreaking gene therapy platform, Prometheus™. This latest funding is set to propel Remedium Bio’s innovative approach to gene therapy into new realms of clinical research and application. Remedium Bio is at the forefront of biotechnology with its Prometheus™…
In a significant boost to the biotech sector, NanoSyrinx, a trailblazer in targeted intracellular delivery technologies, has successfully completed a £10 million financing round. This pivotal investment will accelerate the development of NanoSyrinx’s cutting-edge nano syringe platform, designed to enhance the precision of biologic therapeutic delivery. NanoSyrinx’s innovative approach leverages naturally occurring ‘nano syringes’—microscopic delivery…
Sonoma Biotherapeutics, Inc., a leading clinical-stage biotechnology firm specializing in engineered regulatory T cell (Treg) therapies, has achieved a significant milestone with a $45 million payment from Regeneron Pharmaceuticals, Inc. This milestone underscores the fruitful partnership between the two companies in developing advanced treatments for autoimmune diseases. The payment marks a pivotal point in Sonoma…
eGenesis, a trailblazer in biotechnology with a focus on developing human-compatible engineered organs, has announced the successful completion of a $191 million Series D financing round. This substantial investment will propel the advancement of eGenesis’s lead product candidate, EGEN-2784, through its first-in-human clinical trials for kidney transplants. Additionally, the funds will facilitate the expansion of…
Arsenal Biosciences, Inc. (ArsenalBio), a pioneering force in programmable cell therapy, has announced the successful closure of an oversubscribed $325 million Series C financing round. This significant funding boost reflects a growing confidence in ArsenalBio’s innovative approach to advanced CAR T-cell therapies targeting solid tumors. The Series C round attracted a host of new investors,…
AcuraStem, a leading biotechnology firm renowned for its patient-centered approach to treating neurodegenerative disorders, has announced a pivotal development in its research efforts. The company has been awarded $4 million in grant funding by the California Institute for Regenerative Medicine (CIRM). This substantial investment will bolster AcuraStem’s innovative work on its targeted therapeutic program focusing…
Noetik, a pioneering AI-native biotechnology firm dedicated to advancing precision cancer therapies, has successfully closed a substantial $40 million Series A financing round. This oversubscribed round was spearheaded by Polaris Partners, with Amy Schulman, Managing Partner, joining Noetik’s board of directors. The funding also saw participation from notable new investors including Khosla Ventures, Wittington Ventures,…
